137
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Treatment Success Across Different Levels of Preoperative Disease Burden: Stratified Two-Year Outcomes from the Pivotal Trial of iStent inject® Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract

, , , , &
Pages 3231-3240 | Published online: 03 Aug 2021

References

  • Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013
  • Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126(8):1030–1036. doi:10.1001/archopht.126.8.1030
  • Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma Trial. Arch Ophthalmol. 2003;121(1):48–56. doi:10.1001/archopht.121.1.48
  • Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–720. doi:10.1001/archopht.120.6.714
  • Rathi S, Andrews CA, Greenfield DS, Stein JD. Trends in glaucoma surgeries performed by glaucoma subspecialists versus nonsubspecialists on medicare beneficiaries from 2008 through 2016. Ophthalmology. 2021;128(1):30–38. doi:10.1016/j.ophtha.2020.06.051
  • Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC, Tube Versus Trabeculectomy Study Group. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153(5):804–814. doi:10.1016/j.ajo.2011.10.024
  • Jampel HD, Musch DC, Gillespie BW, Lichter PR, Wright MM, Guire KE, Collaborative Initial Glaucoma Treatment Study Group. Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS). Am J Ophthalmol. 2005;140(1):16–22. doi:10.1016/j.ajo.2005.02.013
  • Wilson MR, Mendis U, Paliwal A, et al. Long-term follow-up of primary glaucoma surgery with Ahmed glaucoma valve implant versus trabeculectomy. Am J Ophthalmol. 2003;136(3):464e470. doi:10.1016/S0002-9394(03)00239-3
  • Kim EA, Law SK, Coleman AL, et al. Long-term bleb-related infections after trabeculectomy: incidence, risk factors, and influence of bleb revision. Am J Ophthalmol. 2015;159(6):1082e1091. doi:10.1016/j.ajo.2015.03.001
  • Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013;131(12):1573–1582. doi:10.1001/jamaophthalmol.2013.5059
  • Samuelson TW, Katz LJ, Wells JM, Duh Y-J, Giamporcaro JE. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118(3):459–467. doi:10.1016/j.ophtha.2010.07.007
  • Ziaei H, Au L. Manchester iStent study: long-term 7-year outcomes. Eye (Lond). 2020. PMID: 33139875. doi:10.1038/s41433-020-01255-6.
  • Neuhann TH, Hornbeak DM, Neuhann RT, Giamporcaro JE. Long-term effectiveness and safety of trabecular micro-bypass stent implantation with cataract surgery in patients with glaucoma or ocular hypertension: 5-year outcomes. J Cataract Refract Surg. 2019;45(3):312–320. doi:10.1016/j.jcrs.2018.10.029
  • Gallardo MJ, Supnet RA. Three-year outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic population with primary open-angle glaucoma. Clin Ophthalmol. 2019;13:869–879. doi:10.2147/OPTH.S189071
  • Ferguson TJ, Mechels KB, Dockter Z, et al. iStent trabecular microbypass stent implantation with phacoemulsification in patients with open-angle glaucoma: 6-year outcomes. Clin Ophthalmol. 2020;14:1859–1866. doi:10.2147/OPTH.S247910
  • Ferguson T, Swan R, Ibach M, Schweitzer J, Sudhagoni R, Berdahl JP. Evaluation of a trabecular microbypass stent with cataract extraction in severe primary open-angle glaucoma. J Glaucoma. 201827(1):71–76. doi:10.1097/IJG.0000000000000825.
  • Ferguson TJ, Swan RJ, Bleeker A, et al. Trabecular microbypass stent implantation in pseudoexfoliative glaucoma: long-term results [published online ahead of print, 2020 May 7]. J Cataract Refract Surg. 2020. doi:10.1097/j.jcrs.0000000000000243
  • Ferguson TJ, Ibach M, Schweitzer J, et al. Trabecular microbypass stent implantation in pseudophakic eyes with open-angle glaucoma: long-term results. J Cataract Refract Surg. 2019;45(4):414–420. doi:10.1016/j.jcrs.2018.11.005
  • Ferguson TJ, Ibach M, Schweitzer J, Karpuk KL, Stephens JD, Berdahl JP. Trabecular microbypass stent implantation with cataract extraction in pigmentary glaucoma. Clin Exp Ophthalmol. 2020;48(1):37–43. doi:10.1111/ceo.13638
  • Nitta K, Yamada Y, Morokado S, Sugiyama K. iStent trabecular micro-bypass stent implantation with cataract surgery in a Japanese glaucoma population. Clin Ophthalmol. 2020;15(14):3381–3391. doi:10.2147/OPTH.S274281
  • Fechtner RD, Voskanyan L, Vold SD, et al. Five-year, prospective, randomized, multi-surgeon trial of two trabecular bypass stents versus prostaglandin for newly-diagnosed open-angle glaucoma. Ophthalmol Glaucoma. 2019;2(3):156–166. doi:10.1016/j.ogla.2019.03.004
  • Chen DZ, Sng CCA, Sangtam T, et al. Phacoemulsification vs phacoemulsification with micro-bypass stent implantation in primary angle closure and primary angle closure glaucoma: a randomized single-masked clinical study. Clin Exp Ophthalmol. 2020;48(4):450–461. doi:10.1111/ceo.13721.
  • Schweitzer JA, Hauser WH, Ibach M, et al. Prospective interventional cohort study of ocular surface disease changes in eyes after trabecular micro-bypass stent(s) implantation (iStent or iStent inject) with phacoemulsification. Ophthalmol Ther. 2020;9(4):941–953. doi:10.1007/s40123-020-00290-6
  • Samuelson TW, Sarkisian SR Jr., Lubeck DM, et al.; for the iStent inject Study Group. Prospective, randomized, controlled pivotal trial of istent inject trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811–821. doi:10.1016/j.ophtha.2019.03.006.
  • Shalaby WS, Jia J, Katz LJ, Lee D. iStent inject®: a comprehensive survey of the literature [published online ahead of print, 2020 Jul 10]. J Cataract Refract Surg. 2020. doi:10.1097/j.jcrs.0000000000000325.
  • Ferguson TJ, Dockter Z, Bleeker A, et al. iStent inject trabecular microbypass stent implantation with cataract extraction in open-angle glaucoma: early clinical experience. Eye Vis (Lond). 2020;7(1):28. doi:10.1186/s40662-020-00194-3
  • Salimi A, Watt H, Harasymowycz P. three-year outcomes of second-generation trabecular micro-bypass stents (iStent inject) with phacoemulsification in various glaucoma subtypes and severities. J Glaucoma. 2020. PMID: 33105306. doi:10.1097/IJG.0000000000001716.
  • Clement C, Howes F, Ioannidis AS, et al. Two-year multicenter outcomes of istent inject trabecular micro-bypass stents combined with phacoemulsification in various types of glaucoma and ocular hypertension. Clin Ophthalmol. 2020;14:3507–3517. doi:10.2147/OPTH.S271646
  • Neuhann R, Neuhann T. Second-generation trabecular micro-bypass stent implantation: retrospective analysis after 12- and 24-month follow-up. Eye Vis (Lond). 2020;7(1):1. doi:10.1186/s40662-019-0169-7
  • Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in various types of glaucoma. Ophthalmol Ther. 2018;7(2):405–415. doi:10.1007/s40123-018-0152-8
  • Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Second-generation trabecular micro-bypass stents as standalone treatment for glaucoma: a 36-month prospective Study. Adv Ther. 2019;36(7):1606–1617. doi:10.1007/s12325-019-00984-9
  • Fea AM, Belda JI, Rekas M, et al. Prospective unmasked randomized evaluation of the iStent inject versus two ocular hypotensive agents in patients with primary open-angle glaucoma. Clin Ophthalmol. 2014;8:875–882.
  • Lindstrom R, Sarkisian SR, Lewis R, Hovanesian J, Voskanyan L. Four-Year Outcomes of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication. Clin Ophthalmol. 2020;14:71–80. doi:10.2147/OPTH.S235293
  • Salimi A, Clement C, Shiu M, Harasymowycz P. Second-generation trabecularmicro-bypass (istent inject) with cataract surgery in eyes with normal-tension glaucoma: one-year outcomes of a multi-centre study [published online ahead of print, 2020 Jul 1]. Ophthalmol Ther. 2020. doi:10.1007/s40123-020-00266-6.
  • Salimi A, Abu-Nada M, Harasymowycz P. Matched cohort study of Cataract surgery with and without trabecular micro-bypass stent implantation in primary angle-closure glaucoma. Am J Ophthalmol. 2021;224:310–320. doi:10.1016/j.ajo.2020.12.032. PMID: 33428885.
  • Guedes RAP, Gravina DM, Lake JC, Guedes VMP, Chaoubah A. One-year comparative evaluation of istent or istent inject implantation combined with cataract surgery in a single center. Adv Ther. 2019;36(10):2797–2810. doi:10.1007/s12325-019-01067-5
  • Manning D. Real-world Case series of istent or istent inject trabecular micro-bypass stents combined with cataract surgery. Ophthalmol Ther. 2019;8(4):549–561. doi:10.1007/s40123-019-00208-x
  • Klabe K Minimally invasive glaucoma surgery: 5 years – results with the iStent inject. Poster Presentation at the Annual Meeting of the European Society of Cataract and Refractive Surgeons (ESCRS Virtual). October 3, 2020.
  • Samuelson TW, Singh IP, Williamson BK, et al. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021;229:220–229. doi:10.1016/j.ajo.2021.03.007. PMID: 33737036.
  • Shingleton BJ, Pasternack JJ, Hung JW, O’Donoghue MW. Three and five year changes in intraocular pressures after clear corneal phacoemulsification in open angle glaucoma patients, glaucoma suspects, and normal patients. J Glaucoma. 2006;15(6):494–498. doi:10.1097/01.ijg.0000212294.31411.92
  • Poley BJ, Lindstrom RL, Samuelson TW. Long-term effects of phacoemulsification with intraocular lens implantation in normotensive and ocular hypertensive eyes. J Cataract Refract Surg. 2008;34(5):735–742. doi:10.1016/j.jcrs.2007.12.045
  • Poley BJ, Lindstrom RL, Samuelson TW, Jr SR. Intraocular pressure reduction after phacoemulsification with intraocular lens implantation in glaucomatous and nonglaucomatous eyes: evaluation of a causal relationship between the natural lens and open-angle glaucoma. J Cataract Refract Surg. 2009;35(11):1946–1955. doi:10.1016/j.jcrs.2009.05.061
  • Mathalone N, Hyams M, Neiman S, Buckman G, Hod Y, Geyer O. Long-term intraocular pressure control after clear corneal phacoemulsification in glaucoma patients. J Cataract Refract Surg. 2005;31(3):479–483. doi:10.1016/j.jcrs.2004.06.046
  • Rothschild P, Komzak K, Hooshmand J, Allen P, Vote B, Toh T. Predictors of success of iStent and iStent inject, when combined with cataract surgery [published online ahead of print, 2020 May 4]. Clin Exp Ophthalmol. 2020. doi:10.1111/ceo.13777.
  • Guedes VM, Chaoubah A. Factors Associated with Unqualified Success After Trabecular Bypass Surgery. A Case-Control Study [published online ahead of print, 2020 Aug 5]. J Glaucoma. 2020. doi:10.1097/IJG.0000000000001626.
  • Hunter K, Fjield T, Heitzmann H, Shandas R, Kahook M. Characterization of micro- invasive trabecular bypass stents by ex vivo perfusion and computational flow modeling. Clin Ophthalmol. 2014;8:499–506.
  • Bahler C, Hann C, Fjield T, Haffner D, Heitzmann H, Fautsch MP. Second-generation trabecular meshwork bypass stent (iStent inject) increases outflow facility in cultured human anterior segments. Am J Ophthalmol. 2012;153(6):1206–1213. doi:10.1016/j.ajo.2011.12.017
  • Huang AS, Penteado RC, Papoyan V, Voskanyan L, Weinreb RN. Aqueous angiographic outflow improvement after trabecular micro-bypass in glaucoma patients. Ophthalmol Glaucoma. 2019;2(1):11–21. doi:10.1016/j.ogla.2018.11.010
  • Samuelson TW, Chang DF, Marquis R, et al.; HORIZON Investigators. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON Study. Ophthalmology. 2019;126(1):29e37. doi:10.1016/j.ophtha.2018.05.012.
  • Lai JSM, Tham CCY, Lam DSC. The efficacy and safety of combined phacoemulsification, intraocular lens implantation, and limited goniosynechialysis, followed by diode laser peripheral iridoplasty, in the treatment of cataract and chronic angle-closure glaucoma. J Glaucoma. 2001;10(4):309–315. doi:10.1097/00061198-200108000-00011
  • Tham CC, Kwong YY, Leung DY, et al. Phacoemulsification versus combined phacotrabeculectomy in medically controlled chronic angle closure glaucoma with cataract. Ophthalmology. 2008;115(12):2167–2173.e2. doi:10.1016/j.ophtha.2008.06.016
  • Konopińska J, Kozera M, Kraśnicki P, Mariak Z, Rekas M. The effectiveness of first-generation istent microbypass implantation depends on initial intraocular pressure: 24-month follow-up—prospective clinical Trial. J Ophthalmol. 2020;2020:1–8. doi:10.1155/2020/8164703. Article ID 8164703.
  • Chansangpetch S, Ittarat M, Yang S, et al. Comparison of 1-Year Effectiveness of Trabecular Microbypass Stent implantation (iStent) in Conjunction With Phacoemulsification Among Mild, Moderate, and Severe Primary Open-angle Glaucoma Patients [published online ahead of print, 2020 May 19]. J Glaucoma. 2020;29(7):542–549. doi:10.1097/IJG.0000000000001542
  • Broadway D, Hitchings R, Grierson I. Topical antiglaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery. J Glaucoma. 1995;4(2):136. doi:10.1097/00061198-199504000-00012
  • Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1–9.e2. doi:10.1016/j.ajo.2011.05.033
  • Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b2
  • Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308–1316. doi:10.1016/j.ophtha.2015.03.026